Wednesday, February 22, 2023 Daily Archives

Eli Lilly: Capacity and access key to launching Mounjaro outside US

by

Eli Lilly expects to double incretin capacity by the end of 2023, driving the launch of once-weekly type 2 diabetes medication Mounjaro (tirzepatide) beyond the US. Type 2 diabetes medication Mounjaro received US Food and Drug Administration (FDA) in May 2022 and pulled in $187 million in its first full quarter, and a further $279.2 in Lilly’s Q4. The once-weekly drug consisting of incretin hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) is an expected blockbuster so long as Lilly…

February 22, 2023

Myeloid to run $96m Australian RNA facility

by

Myeloid Therapeutics has been selected to operate an RNA research and pilot manufacturing plant at Macquarie University in Sydney, Australia. The facility, which will be located at Macquarie University’s Wallumattagal campus, has been called the “first-of-its-kind” in Australia by the New South Wales (NSW) government.  The partnership between Myeloid and the NSW  Government aims to support the State’s ability to develop and produce RNA-based therapeutics and vaccines locally. “The cutting-edge work that will be done at this world-leading facility has…

February 22, 2023